National Pension Service Grows Stock Holdings in Kenvue Inc. $KVUE

National Pension Service raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 1.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,835,972 shares of the company’s stock after buying an additional 31,011 shares during the period. National Pension Service’s holdings in Kenvue were worth $48,921,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of KVUE. Cornerstone Planning Group LLC boosted its position in shares of Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the period. Physician Wealth Advisors Inc. boosted its position in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the period. Elyxium Wealth LLC purchased a new position in shares of Kenvue during the fourth quarter worth $26,000. Golden State Wealth Management LLC boosted its position in shares of Kenvue by 150.1% during the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after buying an additional 1,190 shares during the period. Finally, SBI Securities Co. Ltd. boosted its position in shares of Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after buying an additional 1,027 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.59% of the stock is currently owned by corporate insiders.

Kenvue Trading Up 0.0%

NYSE:KVUE opened at $17.29 on Monday. The firm has a market cap of $33.19 billion, a PE ratio of 20.34, a price-to-earnings-growth ratio of 1.31 and a beta of 0.54. The stock has a fifty day moving average price of $17.40 and a 200 day moving average price of $17.46. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $23.90. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.Kenvue’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business posted $0.24 earnings per share. Sell-side analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on KVUE shares. Weiss Ratings lowered Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. UBS Group decreased their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Citigroup decreased their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Finally, Canaccord Genuity Group lifted their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.